Xvivo Perfusion Publishes Q3 2026 Interim Report Presentation
Bitget2026/10/22 05:43- Xvivo Perfusion's third-quarter 2026 sales rose 34% to SEK 253 million.
- EBITDA increased to SEK 52 million from SEK 36 million; the margin widened to 21% from 19%.
- Thoracic sales reached SEK 177 million, with organic growth of 51%.
- Nine-month sales climbed 25% to SEK 733 million.
- Heart Assist Transport secured CE marking; the FDA received its premarket approval application in September 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
While the industry faces turmoil, "Nvidia-backed" Nscale presses ahead for NYSE listing! New IPO prospectus reveals 1,344% surge in revenue but a quarterly net loss of $1.69 billion
Nscale, a "New Cloud" provider backed by Nvidia, submitted its latest filing for an initial public offering (IPO) in the United States on Thursday.
AI capital expenditures peak as global stock market profits"shift gears"! Goldman Sachs outlines three major themes for 2027
Goldman Sachs Portfolio Strategy Research Department pointed out that as the artificial intelligence investment boom peaks, global stock market earnings growth is expected to decline by more than half in 2027. However, recent valuation declines have created attractive entry points for long-duration technology growth stocks.
Nvidia (NVDA.US) CEO resigns, causing U.S. stocks to fall; Dow Jones drops 189 points
The resignation of Nvidia CEO Jensen Huang has triggered management turmoil, coupled with espionage rumors, leading to a broad decline in the New York stock market on the 12th. The Dow Jones Industrial Average closed down 189.40 points, with the S&P 500 and the Nasdaq Composite also posting losses, and small and mid-cap stocks experiencing the largest declines. Although the long-term outlook for AI remains unchanged, individual corporate governance risks are significantly weighing on the sentiment of the technology sector, driving funds to shift toward competitors and non-tech blue-chip stocks.
US Senate Finance Committee Chair subpoenas Jensen Huang and Lutnick to testify on Nvidia controversy
Crypto prices
More
